EGFR and non-small cell lung carcinoma: Currently, third-generation EGFR TKIs, which are marked for their potent central nervous system (CNS) penetrance, are the standard-of-care (SOC) first-line treatment for advanced-stage EGFR-mutant NSCLC (Cheng et al., 2024; Soria et al., 2018; Ramalingam et al., 2020; Chen et al., 2022).